Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rob Humphrey

Clinical Research Fellow

Rob joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) as a clinical research fellow in January 2024. He is working on both the ASCEND-PLUS trial, assessing oral semaglutide in people with diabetes, and the ORION-4 trial, evaluating the lipid-lowering drug inclisiran in people with pre-exisiting cardiovascular disease.

He will also be working towards completion of a higher degree during his time at CTSU.

Rob studied medicine at the University of Manchester and graduated in 2018, before moving to Oxford in 2020 to pursue specialty training in chemical pathology at the John Radcliffe hospital. Studying part-time, he completed an MSc in clinical biochemistry in 2022.

His subspecialty interests include lipids and metabolic disorders.